Company
Nexstim
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
4
510(k), De Novo and PMA
Device trials
4
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
Recall records
2
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$3.7M
1 Form D offering, 2014 to 2014
Equity
$3.7M
Stock sold for cash
Debt and convertible notes
$0
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: equity, $3.7M raised, first sale Nov 14, 2014, 1 investor.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Nov 14, 2014 | Equity | $3.7M | Open-ended | 1 | Rule 506(b) | Form D ↗Dec 22, 2014 |
Company details
From the company's latest Form D.
- Legal name
- Nexstim Plc
- Headquarters
- Helsinki, Finland
- Incorporated
- Finland over five years before filing
- Entity type
- Public Limited Company
- Revenue range
- Decline to Disclose
- Industry filed under
- Biotechnology
- SEC filer
- CIK 1628859 ↗
Executives, directors and promoters
As listed on the latest Form D.
16 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Nexstim.
Latest FDA decisions
K252358 · Decided Mar 20, 2026 · 234 days after receipt
Device type: Transcranial Magnetic Stimulator (OBP) · Neurology & Neurosurgery
K253098 · Decided Mar 20, 2026 · 178 days after receipt
Device type: Transcranial Magnetic Stimulator (OBP) · Neurology & Neurosurgery
K182700 · Decided Mar 22, 2019 · 176 days after receipt
Device type: Transcranial Magnetic Stimulator (OBP) · Neurology & Neurosurgery
1 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Use of Nexstim SNBT SystemCompleted
NCT05549453 · 12 participants · Start Sep 26, 2022 · Primary completion Dec 31, 2022
Device: Nexstim SNBT use · For: Usability of the Graphical User Interface of the Device for Its Intended Use
Sites: Helsinki, Finland
NCT03010462 · 60 participants · Start Mar 1, 2017 · Primary completion Aug 15, 2018
Device: Nexstim NBS guided active rTMS; Nexstim NBS guided sham rTMS · For: Ischemic Stroke
Sites: Downey, California; Chicago, Illinois; Boston, Massachusetts · 5 sites in all
- Niche Trial: Navigated Inhibitory rTMS to Contralesional Hemisphere TrialPivotal-lookingCompleted
NCT02089464 · 199 participants · Start Apr 2014 · Primary completion May 2016
Device: NBS-guided rTMS; Sham rTMS · For: Stroke
Sites: Phoenix, Arizona; Downey, California; Atlanta, Georgia · 12 sites in all
1 more trials with a free account
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2319-2017 · Started Mar 14, 2017 · Posted by FDA May 22, 2017
Reason given: Software defect: the NBS software may accidentally generate duplicate copies of one or several files.
Cause as FDA categorized it: Use error · Device type: Stimulator, Electrical, Evoked Response (GWF)
Z-2320-2017 · Started Mar 14, 2017 · Posted by FDA May 22, 2017
Reason given: Software defect: the NBS software may accidentally generate duplicate copies of one or several files.
Cause as FDA categorized it: Use error · Device type: Stimulator, Electrical, Evoked Response (GWF)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.